The Food and Drug Administration (FDA) on Monday granted approval for the first new Alzheimer’s treatment since 2003. The decision comes as the debate over whether to approve Biogen’s drug aducanumab has stirred controversy, with some Alzheimer’s experts and an independent advisory committee opposing approval saying there’s not enough evidence that the drug is effective. […]
